Abstract:Objective To observe the efficacy,side effect and health economics values of the therapy of antidepressants combining atypical antipsychotics with different administration lengths,on nonpsychotic symptom,treatment-resistant depression. Methods 99 patients out of the randomized 4 groups of patients completed one year follow-up study.The 4 groups are the group of single therapy of fluoxetine(27 patients),the group of therapy of fluoxetine combining 1~2 months administration of olanzapine(28 patients),the group of therapy of fluoxetine combining 4~6 months administration of olanzapine(29 patients) and the group of therapy of fluoxetine combining 12 months administration of olanzapine(15 patients).At the starting point,measure of all patients in the four groups the HAMD,SDSS,weight and annual income ete at the end of 1 year follow-up study,measure of those patients the HAMD,weight.TESS and income of the past year,working hours,recurrent frequency and therapeutic sosts etc.The decreased scores of HAMD tests and the cure rates are used to evaluate the efficacy,the TESS scores and weight records are used to evaluate the side effect,and the working hours,annual income and therapeutic costs are used to evaluate the health economics values. Results All patients of the four groups improved at different degree comparing to their pre-therapeutic period.The group of therapy of fluoxetine combining 4~6 months administration of olanzapine and the group of therapy of fluoxetine combining 12 months administration of olanzapine were improved more significantly than the other two groups.No patients in the four groups showed severe side effects,but patients of the three groups of combination therapy had weight increase at different degree comparing with the fluoxetine single using group.In terms of annual income,working hours and recurrent frequency,the 4~6 months olanzapine combination group and the 12 months olanzapine combination group are superior to the other two groups.The 4~6 months olanzapine combination group is at lower therapeutic cost than the 12 months olanzapine combination group. Conclusions Therapy of olanzapine,the atypical antipsychotics,combining fluoxetine on nonpsychotic symptom,treatment-resistant depression has definite curative effect and less side effects.The most appropricate administration length of olanzapine in the combination is 4~6 months..

Olanzapine add-on treatment promotes neuronal differentiation of neural stem cells compared with fluoxetine alone

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

A controlled trial of olanzapine and fluoxetine in treatment of negative symptoms of schizophrenia

The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain

Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats.

Olanzapine Enhances Early Brain Maturation Through Activation of the NODAL/FOXH1 Axis

A Novel Cognitive Enhancer, Zset1446/St101, Promotes Hippocampal Neurogenesis and Ameliorates Depressive Behavior in Olfactory Bulbectomized Mice

A study of olanzapine and fluoxetine combination therapy on nonpsychotic symptom,treatment-resistant depression

Fluoxetine Regulates Neurogenesis in Vitro Through Modulation of GSK-3β/β-catenin Signaling.

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

β-arrestin 2 is essential for fluoxetine-mediated promotion of hippocampal neurogenesis in a mouse model of depression

Novel cognitive enhancer, ZSET1446 promotes neurogenesis in the hippocampal dentate gyrus and improves depressive behavior in the olfactory bulbectomized mice.

Requirement of hippocampal DG nNOS-CAPON dissociation for the anxiolytic and antidepressant effects of fluoxetine

Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period.

P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats

Randomized Double-Blind Control Study of Olanzapine Augmented with Fluoxetine for Schizophrenia with Depression Symptom

A study on efficacy and safety of fluoxetine combined with olanzapine in the treatment of major depression

Olanzapine Ameliorates Neuropathological Changes and Increases IGF-1 Expression in Frontal Cortex of C57BL/6 Mice Exposed to Cuprizone.

Sertraline Promotes Hippocampus-Derived Neural Stem Cells Differentiating into Neurons but Not Glia and Attenuates LPS-induced Cellular Damage

Olanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1